Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2004 Oct;59(10):843–849. doi: 10.1136/thx.2004.022541

Chronic obstructive pulmonary disease in α1-antitrypsin PI MZ heterozygotes: a meta-analysis

C Hersh 1, M Dahl 1, N Ly 1, C Berkey 1, B Nordestgaard 1, E Silverman 1
PMCID: PMC1746834  PMID: 15454649

Abstract

Background: Severe α1-antitrypsin deficiency, usually related to homozygosity for the protease inhibitor (PI) Z allele, is a proven genetic risk factor for chronic obstructive pulmonary disease (COPD). The risk of COPD in PI MZ heterozygous individuals is controversial.

Methods: A search of MEDLINE from January 1966 to May 2003 identified studies that examined the risk of COPD in PI MZ individuals and studies that measured forced expiratory volume in 1 second (FEV1) in heterozygotes.

Results: In 16 studies that reported COPD as a categorical outcome, the combined odds ratio (OR) for PI MZ versus PI MM (normal genotype) was 2.31 (95% CI 1.60 to 3.35). The summary OR was higher in case-control studies (OR 2.97; 95% CI 2.08 to 4.26) than in cross sectional studies (OR 1.50; 95% CI 0.97 to 2.31) and was attenuated in studies that adjusted for cigarette smoking (OR 1.61; 95% CI 0.92 to 2.81). In seven studies that reported FEV1 as a continuous outcome there was no difference in mean FEV1 between PI MM and PI MZ individuals.

Conclusions: Case-control studies showed increased odds of COPD in PI MZ individuals, but this finding was not confirmed in cross sectional studies. Variability in study design and quality limits the interpretation. These results are consistent with a small increase in risk of COPD in all PI MZ individuals or a larger risk in a subset. Future studies that adjust for smoking and include other COPD related phenotypes are required to conclusively determine the risk of COPD in PI MZ heterozygotes.

Full Text

The Full Text of this article is available as a PDF (165.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abboud R. T., Rushton J. M., Grzybowski S. Interrelationships between neutrophil elastase, serum alpha, -antitrypsin, lung function and chest radiography in patients with chronic airflow obstruction. Am Rev Respir Dis. 1979 Jul;120(1):31–40. doi: 10.1164/arrd.1979.120.1.31. [DOI] [PubMed] [Google Scholar]
  2. Alvarez-Granda L., Cabero-Perez M. J., Bustamante-Ruiz A., Gonzalez-Lamuño D., Delgado-Rodriguez M., García-Fuentes M. PI SZ phenotype in chronic obstructive pulmonary disease. Thorax. 1997 Jul;52(7):659–661. doi: 10.1136/thx.52.7.659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barnett T. B., Gottovi D., Johnson A. M. Protease inhibitors in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1975 May;111(5):587–593. doi: 10.1164/arrd.1975.111.5.587. [DOI] [PubMed] [Google Scholar]
  4. Bartmann K., Fooke-Achterrath M., Koch G., Nagy I., Schütz I., Weis E., Zierski M. Heterozygosity in the Pi-system as a pathogenetic cofactor in chronic obstructive pulmonary disease (COPD). Eur J Respir Dis. 1985 Apr;66(4):284–296. [PubMed] [Google Scholar]
  5. Bencze K., Sabatke L., Fruhmann G. Alpha 1-antitrypsin: the PiMM subtypes. Do they play a role in development of chronic obstructive pulmonary diseases? Chest. 1980 Jun;77(6):761–763. doi: 10.1378/chest.77.6.761. [DOI] [PubMed] [Google Scholar]
  6. Berend N. Epidemiological survey of chronic obstructive pulmonary disease and alpha-1-antitrypsin deficiency in Australia. Respirology. 2001 Jun;6 (Suppl):S21–S25. doi: 10.1046/j.1440-1843.2001.00308.x. [DOI] [PubMed] [Google Scholar]
  7. Blanco I., Bustillo E. F., Rodriguez M. C. Distribution of alpha1-antitrypsin PI S and PI Z frequencies in countries outside Europe: a meta-analysis. Clin Genet. 2001 Dec;60(6):431–441. doi: 10.1034/j.1399-0004.2001.600605.x. [DOI] [PubMed] [Google Scholar]
  8. Bruce R. M., Cohen B. H., Diamond E. L., Fallat R. J., Knudson R. J., Lebowitz M. D., Mittman C., Patterson C. D., Tockman M. S. Collaborative study to assess risk of lung disease in Pi MZ phenotype subjects. Am Rev Respir Dis. 1984 Sep;130(3):386–390. doi: 10.1164/arrd.1984.130.3.386. [DOI] [PubMed] [Google Scholar]
  9. Bruun-Petersen K., Bruun-Petersen G., Dahl R., Larsen B., Kølvraa S., Koch J., Bolund L., Gregersen N. Alpha 1-antitrypsin alleles in patients with pulmonary emphysema, detected by DNA amplification (PCR) and oligonucleotide probes. Eur Respir J. 1992 May;5(5):531–537. [PubMed] [Google Scholar]
  10. Buist A. S., Sexton G. J., Azzam A. M., Adams B. E. Pulmonary function in heterozygotes for alpha,-antitrypsin deficiency: a case-control study. Am Rev Respir Dis. 1979 Oct;120(4):759–766. doi: 10.1164/arrd.1979.120.4.759. [DOI] [PubMed] [Google Scholar]
  11. Camara M., Martin J. P. Le déficit en alpha 1-antitrypsine et son retentissement en pathologie pulmonaire. Bull Eur Physiopathol Respir. 1978 Jan-Feb;14(1):91–124. [PubMed] [Google Scholar]
  12. Chan-Yeung M., Ashley M. J., Corey P., Maledy H. Pi phenotypes and the prevalence of chest symptoms and lung function abnormalities in workers employed in dusty industris. Am Rev Respir Dis. 1978 Feb;117(2):239–245. doi: 10.1164/arrd.1978.117.2.239. [DOI] [PubMed] [Google Scholar]
  13. Cohen B. H., Ball W. C., Jr, Bias W. B., Brashears S., Chase G. A., Diamond E. L., Hsu S. H., Kreiss P., Levy D. A., Menkes H. A. A genetic-epidemiologic study of chronic obstructive pulmonary disease. I. Study design and preliminary observations. Johns Hopkins Med J. 1975 Sep;137(3):95–104. [PubMed] [Google Scholar]
  14. Cohen B. H., Ball W. C., Jr, Brashears S., Diamond E. L., Kreiss P., Levy D. A., Menkes H. A., Permutt S., Tockman M. S. Risk factors in chronic obstructive pulmonary disease (COPD). Am J Epidemiol. 1977 Mar;105(3):223–232. doi: 10.1093/oxfordjournals.aje.a112378. [DOI] [PubMed] [Google Scholar]
  15. Cole R. B., Nevin N. C., Blundell G., Merrett J. D., McDonald J. R., Johnston W. P. Relation of alpha-1-antitrypsin phenotype to the performance of pulmonary function tests and to the prevalence of respiratory illness in a working population. Thorax. 1976 Apr;31(2):149–157. doi: 10.1136/thx.31.2.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Colp C., Talavera W., Goldman D., Green J., Multz A., Lieberman J. Profile of bronchospastic disease in Puerto Rican patients in New York City. A possible relationship to alpha 1-antitrypsin variants. Arch Intern Med. 1990 Nov;150(11):2349–2354. [PubMed] [Google Scholar]
  17. Cooper D. M., Hoeppner V., Cox D., Zamel N., Bryan A. C., Levison H. Lung function in alpha1-antitrypsin heterozygotes (Pi type MZ). Am Rev Respir Dis. 1974 Dec;110(6):708–715. doi: 10.1164/arrd.1974.110.6P1.708. [DOI] [PubMed] [Google Scholar]
  18. Corbo G. M., Forastiere F., Agabiti N., Dell'Orco V., Pistelli R., Massi G., Perucci C. A., Valente S. Passive smoking and lung function in alpha(1)-antitrypsin heterozygote schoolchildren. Thorax. 2003 Mar;58(3):237–241. doi: 10.1136/thorax.58.3.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cox D. W., Hoeppner V. H., Levison H. Protease inhibitors in patients with chronic obstructive pulmonary disease: the alpha-antitrypsin heterozygote controversy. Am Rev Respir Dis. 1976 May;113(5):601–606. doi: 10.1164/arrd.1976.113.5.601. [DOI] [PubMed] [Google Scholar]
  20. Dahl M., Nordestgaard B. G., Lange P., Vestbo J., Tybjaerg-Hansen A. Molecular diagnosis of intermediate and severe alpha(1)-antitrypsin deficiency: MZ individuals with chronic obstructive pulmonary disease may have lower lung function than MM individuals. Clin Chem. 2001 Jan;47(1):56–62. [PubMed] [Google Scholar]
  21. Dahl Morten, Tybjaerg-Hansen Anne, Lange Peter, Vestbo Jørgen, Nordestgaard Børge G. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: A longitudinal study of the general population. Ann Intern Med. 2002 Feb 19;136(4):270–279. doi: 10.7326/0003-4819-136-4-200202190-00006. [DOI] [PubMed] [Google Scholar]
  22. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  23. Duncan P. E., Griffin J. P. Physiological studies in a large sibship with antitrypsin deficiency. Br J Dis Chest. 1975 Apr;69(2):107–117. [PubMed] [Google Scholar]
  24. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13;315(7109):629–634. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Eriksson S., Lindell S. E., Wiberg R. Effects of smoking and intermediate alpha 1-antitrypsin deficiency (PiMZ) on lung function. Eur J Respir Dis. 1985 Oct;67(4):279–285. [PubMed] [Google Scholar]
  26. Eriksson S., Moestrup T., Hägerstrand I. Liver, lung and malignant disease in heterozygous (Pi MZ) alpha1-antitrypsin deficiency. Acta Med Scand. 1975 Oct;198(4):243–247. doi: 10.1111/j.0954-6820.1975.tb19535.x. [DOI] [PubMed] [Google Scholar]
  27. Fagerhol M. K., Hauge H. E. Serum Pi types in patients with pulmonary diseases. Acta Allergol. 1969 May;24(2):107–114. doi: 10.1111/j.1398-9995.1969.tb03760.x. [DOI] [PubMed] [Google Scholar]
  28. Fallat R., Powell M., Kueppers F., Nadel J., Murray J. Chronic obstructive pulmonary disease with intermediate alpha-1-antitrypsin deficiency. Chest. 1971 May;59(Suppl):20S+–20S+. doi: 10.1016/s0012-3692(15)31571-3. [DOI] [PubMed] [Google Scholar]
  29. Galdston M., Melnick E. L., Goldring R. M., Levytska V., Curasi C. A., Davis A. L. Interactions of neutrophil elastase, serum trypsin inhibitory activity, and smoking history as risk factors for chronic obstructive pulmonary disease in patients with MM, MZ, and ZZ phenotypes for alpha-antitrypsin. Am Rev Respir Dis. 1977 Nov;116(5):837–846. doi: 10.1164/arrd.1977.116.5.837. [DOI] [PubMed] [Google Scholar]
  30. Gelb A. F., Klein E., Lieberman J. Pulmonary function in nonsmoking subjects with alpha1 antitrypsin deficiency (MZ phenotype). Am J Med. 1977 Jan;62(1):93–98. doi: 10.1016/0002-9343(77)90354-0. [DOI] [PubMed] [Google Scholar]
  31. Gerblich A. A., Kleinerman J., Rynbrandt D. J., Chester E. H., Ihrig J. Pi-Z phenotypes in a pulmonary clinic. Their prevalence and physiologic state. Am J Clin Pathol. 1978 May;69(5):509–513. doi: 10.1093/ajcp/69.5.509. [DOI] [PubMed] [Google Scholar]
  32. Girard F., Aug F., Camara M., Bohadana A. B., Bagrel A., Museur G., Abraham S. Bilan pulmonaire et déficit hétérozygote en alpha 1-antitrypsine au sein d'une population active générale. Bull Eur Physiopathol Respir. 1978 Jan-Feb;14(1):11–22. [PubMed] [Google Scholar]
  33. Gishen P., Saunders A. J., Tobin M. J., Hutchison D. C. Alpha 1-antitrypsin deficiency: the radiological features of pulmonary emphysema in subjects of Pi type Z and Pi type SZ: a survey by the British Thoracic Association. Clin Radiol. 1982 Jul;33(4):371–377. doi: 10.1016/s0009-9260(82)80297-3. [DOI] [PubMed] [Google Scholar]
  34. Gulsvik A., Fagerhol M. K. Alpha 1-antitrypsin phenotypes and obstructive lung disease in the city of Oslo. Scand J Respir Dis. 1979 Oct;60(5):267–274. [PubMed] [Google Scholar]
  35. Gupta S. P., Pande J. N., Guleria J. S. Pulmonary emphysema and alpha-1 antitrypsin deficiency. Indian J Med Res. 1977 Jul;66(1):127–132. [PubMed] [Google Scholar]
  36. Haack D. G. Interactions of neutrophil elastase, serum trypsin inhibitory activity, and smoking history as risk factors for chronic obstructive pulmonary disease in patients with MM, MZ, and ZZ phenotypes for alpha1-antitrypsin. Am Rev Respir Dis. 1978 Apr;117(4):812–813. doi: 10.1164/arrd.1978.117.4.812. [DOI] [PubMed] [Google Scholar]
  37. Hall W. J., Hyde R. W., Schwartz R. H., Mudholkar G. S., Webb D. R., Chaubey Y. P., Townes P. L. Pulmonary abnormalities in intermediate alpha-1-antitrypsin deficiency. J Clin Invest. 1976 Nov;58(5):1069–1077. doi: 10.1172/JCI108558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Hepper N. G., Black L. F., Gleich G. J., Kueppers F. The prevalence of alpha 1-antitrypsin deficiency in selected groups of patients with chronic obstructive lung disease. Mayo Clin Proc. 1969 Oct;44(10):697–710. [PubMed] [Google Scholar]
  39. Hepper N. G., Muhm J. R., Sheehan W. C., Kueppers F., Offord K. P. Roentgenographic study of chronic obstructive pulmonary disease by alpha1-antitrypsin phenotype. Mayo Clin Proc. 1978 Mar;53(3):166–172. [PubMed] [Google Scholar]
  40. Horne S. L., Tennent R. K., Cockcroft D. W., Cotton D. J., Dosman J. A. Pulmonary function in Pi M and MZ grainworkers. Chest. 1986 Jun;89(6):795–799. doi: 10.1378/chest.89.6.795. [DOI] [PubMed] [Google Scholar]
  41. Horton F. O., 3rd, Mackenthun A. V., Anderson P. S., Jr, Patterson C. D., Hammarsten J. F. Alpha 1 antitrypsin heterozygotes (Pi type MZ). A longitudinal study of the risk of development of chronic air flow limitation. Chest. 1980 Feb;77(2 Suppl):261–264. doi: 10.1378/chest.77.2_supplement.261-a. [DOI] [PubMed] [Google Scholar]
  42. Hutchison D. C. Homozygous and heterozygous alpha-1-antitrypsin deficiency: prevalence in pulmonary emphysema. Proc R Soc Med. 1976 Feb;69(2):130–131. doi: 10.1177/003591577606900220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Hutchison D. C., Tobin M. J., Cook P. J. Alpha 1 antitrypsin deficiency: clinical and physiological features in heterozygotes of Pi type SZ. A survey by the British Thoracic Association. Br J Dis Chest. 1983 Jan;77(1):28–34. doi: 10.1016/0007-0971(83)90003-7. [DOI] [PubMed] [Google Scholar]
  44. Janus E. D. Alpha 1-antitrypsin Pi types in COPD patients. Chest. 1988 Aug;94(2):446–447. doi: 10.1378/chest.94.2.446. [DOI] [PubMed] [Google Scholar]
  45. Johnson T. F., Reisman R. E., Arbesman C. E., Mattar A. G., Murphey W. H. Obstructive airway disease associated with heterozygous alpha-1-antitrypsin deficiency. J Allergy Clin Immunol. 1976 Jul;58(1 Pt 1):69–75. doi: 10.1016/0091-6749(76)90108-1. [DOI] [PubMed] [Google Scholar]
  46. Kabiraj M. U., Simonsson B. G., Groth S., Björklund A., Bülow K., Lindell S. E. Bronchial reactivity, smoking, and alpha1-antitrypsin. A population-based study of middle-aged men. Am Rev Respir Dis. 1982 Nov;126(5):864–869. doi: 10.1164/arrd.1982.126.5.864. [DOI] [PubMed] [Google Scholar]
  47. Kambe M., Morishita K., Tsubokura T., Tsuno K., Kimura T., Utsumi T., Kawamoto H., Yamakido M., Mittman C. A study on the lung function in alpha 1-antitrypsin-deficient (PiMZ) patients. Hiroshima J Med Sci. 1993 Mar;42(1):41–45. [PubMed] [Google Scholar]
  48. Kauffmann F. Genetics of chronic obstructive pulmonary diseases. Searching for their heterogeneity. Bull Eur Physiopathol Respir. 1984 Mar-Apr;20(2):163–210. [PubMed] [Google Scholar]
  49. Kauffmann F., Kleisbauer J. P., Cambon-De-Mouzon A., Mercier P., Constans J., Blanc M., Rouch Y., Feingold N. Genetic markers in chronic air-flow limitation. A genetic epidemiologic study. Am Rev Respir Dis. 1983 Mar;127(3):263–269. doi: 10.1164/arrd.1983.127.3.263. [DOI] [PubMed] [Google Scholar]
  50. Klasen E. C., Biemond I., Laros C. D. Alpha 1-antitrypsin deficiency and the flaccid lung syndrome. The heterozygote controversy. Clin Genet. 1986 Mar;29(3):211–215. [PubMed] [Google Scholar]
  51. Klayton R., Fallat R., Cohen A. B. Determinants of chronic obstructive pulmonary disease in patients with intermediate levels of alpha-antitrypsin. Am Rev Respir Dis. 1975 Jul;112(1):71–75. doi: 10.1164/arrd.1975.112.1.71. [DOI] [PubMed] [Google Scholar]
  52. Kozarevic D., Laban M., Budimir M., Vojvodic N., Roberts A., Gordon T., McGee D. L. Intermediate alpha1-antitrypsin deficiency and chronic obstructive pulmonary disease in Yugoslavia. Am Rev Respir Dis. 1978 Jun;117(6):1039–1043. doi: 10.1164/arrd.1978.117.6.1039. [DOI] [PubMed] [Google Scholar]
  53. Kueppers F. Alpha-1-antitrypsin: 1. Evidence for two genes causing low concentrations in serum; 2. Association of heterozygosity and chronic obstructive lung disease. Chest. 1971 May;59(Suppl):15S+–15S+. doi: 10.1378/chest.59.5_supplement.15s. [DOI] [PubMed] [Google Scholar]
  54. Kueppers F., Dönhardt A. Obstructive lung disease in heterozygotes for alpha-1 antitrypsin deficiency. Ann Intern Med. 1974 Feb;80(2):209–212. doi: 10.7326/0003-4819-80-2-209. [DOI] [PubMed] [Google Scholar]
  55. Kueppers F., Fallat R., Larson R. K. Obstructive lung disease and alpha-1-antitrypsin deficiency gene heterozygosity. Science. 1969 Aug 29;165(3896):899–901. doi: 10.1126/science.165.3896.899. [DOI] [PubMed] [Google Scholar]
  56. Kueppers F., Miller R. D., Gordon H., Hepper N. G., Offord K. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med. 1977 Sep;63(3):336–342. doi: 10.1016/0002-9343(77)90270-4. [DOI] [PubMed] [Google Scholar]
  57. Larsson C., Dirksen H., Sundström G., Eriksson S. Lung function studies in asymptomatic individuals with moderately (Pi SZ) and severely (Pi Z) reduced levels of alpha1-antitrypsin. Scand J Respir Dis. 1976;57(6):267–280. [PubMed] [Google Scholar]
  58. Larsson C., Eriksson S., Dirksen H. Smoking and intermediate alpha1-antitrypsin deficiency and lung function in middle-aged men. Br Med J. 1977 Oct 8;2(6092):922–925. doi: 10.1136/bmj.2.6092.922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Lebowitz M. D., Knudson R. J., Morse J. O., Armet D. Closing volume and flow volume abnormalities in alpha(1)-antitrypsin phenotype groups in a community population. Am Rev Respir Dis. 1978 Jan;117(1):179–181. doi: 10.1164/arrd.1978.117.1.179. [DOI] [PubMed] [Google Scholar]
  60. Lieberman J., Colp C. A role for intermediate, heterozygous alpha 1-antitrypsin deficiency in obstructive lung disease. Chest. 1990 Sep;98(3):522–523. doi: 10.1378/chest.98.3.522. [DOI] [PubMed] [Google Scholar]
  61. Lieberman J. Heterozygous and homozygous alpha-antitrypsin deficiency in patients with pulmonary emphysema. N Engl J Med. 1969 Aug 7;281(6):279–284. doi: 10.1056/NEJM196908072810601. [DOI] [PubMed] [Google Scholar]
  62. Lieberman J., Mittman C., Schneider A. S. Screening for homozygous and heterozygous alpha 1-antitrypsin deficiency. Protein electrophoresis on cellulose acetate membranes. JAMA. 1969 Dec 15;210(11):2055–2060. [PubMed] [Google Scholar]
  63. Lieberman J., Winter B., Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986 Mar;89(3):370–373. doi: 10.1378/chest.89.3.370. [DOI] [PubMed] [Google Scholar]
  64. Lomas D. A., Silverman E. K. The genetics of chronic obstructive pulmonary disease. Respir Res. 2001 Jan 11;2(1):20–26. doi: 10.1186/rr34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Madison R., Mittman C., Afifi A. A., Zelman R. Risk factors for obstructive lung disease. Am Rev Respir Dis. 1981 Aug;124(2):149–153. doi: 10.1164/arrd.1981.124.2.149. [DOI] [PubMed] [Google Scholar]
  66. Madison R., Zelman R., Mittman C. Inherited risk factors for chronic lung disease. Chest. 1980 Feb;77(2 Suppl):255–257. doi: 10.1378/chest.77.2_supplement.255. [DOI] [PubMed] [Google Scholar]
  67. Matzen R. N., Bader P. I., Block W. D. alpha1-Antitrypsin deficiency in clinic patients. Ann Clin Res. 1977 Apr;9(2):88–92. [PubMed] [Google Scholar]
  68. McDonagh D. J., Nathan S. P., Knudson R. J., Lebowitz M. D. Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. Physiological comparison of adult normal and heterozygous protease inhibitor phenotype subjects from a random population. J Clin Invest. 1979 Feb;63(2):299–309. doi: 10.1172/JCI109303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Miller R. D., Hepper N. G., Kueppers F., Gordon H., Offord K. P. Host factors in chronic obstructive pulmonary disease in an upper Midwest rural community. Design, case selection, and clinical characteristics in a matched-pair study. Mayo Clin Proc. 1976 Nov;51(11):709–715. [PubMed] [Google Scholar]
  70. Mittman C., Barbela T., Lieberman J. Alpha 1 -antitrypsin deficiency as an indicator of susceptibility to pulmonary disease. J Occup Med. 1973 Jan;15(1):33–38. [PubMed] [Google Scholar]
  71. Mittman C., Barbela T., Lieberman J. Antitrypsin deficiency and abnormal protease inhibitor phenotypes. Arch Environ Health. 1973 Sep;27(3):201–206. doi: 10.1080/00039896.1973.10666352. [DOI] [PubMed] [Google Scholar]
  72. Mittman C., Lieberman J., Marasso F., Miranda A. Smoking and chronic obstructive lung disease in alpha-1-antitrypsin deficiency. Chest. 1971 Sep;60(3):214–221. doi: 10.1378/chest.60.3.214. [DOI] [PubMed] [Google Scholar]
  73. Mittman C., Lieberman J., Rumsfeld J. Prevalence of abnormal protease inhibitor phenotypes in patients with chronic obstructive lung disease. Am Rev Respir Dis. 1974 Feb;109(2):295–296. doi: 10.1164/arrd.1974.109.2.295. [DOI] [PubMed] [Google Scholar]
  74. Mittman C. The PiMZ phenotype: is it a significant risk factor for the development of chronic obstructive lung disease? Am Rev Respir Dis. 1978 Oct;118(4):649–652. doi: 10.1164/arrd.1978.118.4.649. [DOI] [PubMed] [Google Scholar]
  75. Morse J. O., Lebowitz M. D., Knudson R. J., Burrows B. Relation of protease inhibitor phenotypes to obstructive lung diseases in a community. N Engl J Med. 1977 May 26;296(21):1190–1194. doi: 10.1056/NEJM197705262962102. [DOI] [PubMed] [Google Scholar]
  76. Novoradovsky A., Brantly M. L., Waclawiw M. A., Chaudhary P. P., Ihara H., Qi L., Eissa N. T., Barnes P. M., Gabriele K. M., Ehrmantraut M. E. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in alpha1-antitrypsin deficiency. Am J Respir Cell Mol Biol. 1999 Mar;20(3):441–447. doi: 10.1165/ajrcmb.20.3.3144. [DOI] [PubMed] [Google Scholar]
  77. Ostrow D. N., Cherniack R. M. The mechanical properties of the lungs in intermediate deficiency of 1 -antitrypsin. Am Rev Respir Dis. 1972 Sep;106(3):377–383. doi: 10.1164/arrd.1972.106.3.377. [DOI] [PubMed] [Google Scholar]
  78. Ostrow D. N., Manfreda J., Dorman T., Cherniack R. M. Alpha1-antitrypsin phenotypes and lung function in a moderately polluted northern Ontario community. Can Med Assoc J. 1978 Mar 18;118(6):669–672. [PMC free article] [PubMed] [Google Scholar]
  79. Piitulainen E., Sveger T. Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alpha1-antitrypsin deficiency. Acta Paediatr. 1998 Nov;87(11):1120–1124. doi: 10.1080/080352598750031095. [DOI] [PubMed] [Google Scholar]
  80. Poller W., Meisen C., Olek K. DNA polymorphisms of the alpha 1-antitrypsin gene region in patients with chronic obstructive pulmonary disease. Eur J Clin Invest. 1990 Feb;20(1):1–7. doi: 10.1111/j.1365-2362.1990.tb01769.x. [DOI] [PubMed] [Google Scholar]
  81. Pride N. B., Tattersall S. F., Pereira R. P., Hunter D., Blundell G. Lung distensibility and airway function in intermediate alpha 1-antitrypsin deficiency (PiMZ). Chest. 1980 Feb;77(2 Suppl):253–255. [PubMed] [Google Scholar]
  82. Pritchard J. K., Rosenberg N. A. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet. 1999 Jul;65(1):220–228. doi: 10.1086/302449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Roberts A., Kagan A., Rhoads G. G., Pierce J. A., Bruce R. M. Antitrypsin and chronic obstructive pulmonary disease among Japanese-American men. Chest. 1977 Oct;72(4):489–491. doi: 10.1378/chest.72.4.489. [DOI] [PubMed] [Google Scholar]
  84. Sandford A. J., Chagani T., Weir T. D., Connett J. E., Anthonisen N. R., Paré P. D. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med. 2001 Feb;163(2):469–473. doi: 10.1164/ajrccm.163.2.2006158. [DOI] [PubMed] [Google Scholar]
  85. Sandford A. J., Weir T. D., Paré P. D. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J. 1997 Jun;10(6):1380–1391. doi: 10.1183/09031936.97.10061380. [DOI] [PubMed] [Google Scholar]
  86. Sandford A. J., Weir T. D., Spinelli J. J., Paré P. D. Z and S mutations of the alpha1-antitrypsin gene and the risk of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 1999 Feb;20(2):287–291. doi: 10.1165/ajrcmb.20.2.3177. [DOI] [PubMed] [Google Scholar]
  87. Seersholm N., Kok-Jensen A. Intermediate alpha 1-antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema? Respir Med. 1998 Feb;92(2):241–245. doi: 10.1016/s0954-6111(98)90102-0. [DOI] [PubMed] [Google Scholar]
  88. Seersholm N., Wilcke J. T., Kok-Jensen A., Dirksen A. Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med. 2000 Jan;161(1):81–84. doi: 10.1164/ajrccm.161.1.9812131. [DOI] [PubMed] [Google Scholar]
  89. Shah A. C., Dixit S. D., Billimoria F. P., Merchant H. C., Unawala J. Occurrence of alpha 1-antitrypsin deficiency in normal healthy Indians and in patients with various pulmonary diseases. J Indian Med Assoc. 1983 Sep;81(5-6):79–82. [PubMed] [Google Scholar]
  90. Shigeoka J. W., Hall W. J., Hyde R. W., Schwartz R. H., Mudholkar G. S., Speers D. M., Lin C. C. The prevalence of alpha-antitrypsin heterozygotes (Pi MZ) in patients with obstructive pulmonary disease. Am Rev Respir Dis. 1976 Dec;114(6):1077–1084. doi: 10.1164/arrd.1976.114.6.1077. [DOI] [PubMed] [Google Scholar]
  91. Shim Y. S. Epidemiological survey of chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency in Korea. Respirology. 2001 Jun;6 (Suppl):S9–11. doi: 10.1046/j.1440-1843.2001.00305.x. [DOI] [PubMed] [Google Scholar]
  92. Siekmeier R., Schiller-Scotland C. F. Convective gas mixing, airway dimensions and lung function parameters in patients homo- or heterozygote for hereditary alpha1-antitrypsin deficiency. Toxicol Lett. 1998 Aug;96-97:325–333. doi: 10.1016/s0378-4274(98)00089-7. [DOI] [PubMed] [Google Scholar]
  93. Silva Graciela E., Sherrill Duane L., Guerra Stefano, Barbee Robert A. A longitudinal study of alpha1-antitrypsin phenotypes and decline in FEV1 in a community population. Chest. 2003 May;123(5):1435–1440. doi: 10.1378/chest.123.5.1435. [DOI] [PubMed] [Google Scholar]
  94. Silverman E. K., Miletich J. P., Pierce J. A., Sherman L. A., Endicott S. K., Broze G. J., Jr, Campbell E. J. Alpha-1-antitrypsin deficiency. High prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis. 1989 Oct;140(4):961–966. doi: 10.1164/ajrccm/140.4.961. [DOI] [PubMed] [Google Scholar]
  95. Silverman E. K., Palmer L. J. Case-control association studies for the genetics of complex respiratory diseases. Am J Respir Cell Mol Biol. 2000 Jun;22(6):645–648. doi: 10.1165/ajrcmb.22.6.f191. [DOI] [PubMed] [Google Scholar]
  96. Silverman E. K., Province M. A., Rao D. C., Pierce J. A., Campbell E. J. A family study of the variability of pulmonary function in alpha 1-antitrypsin deficiency. Quantitative phenotypes. Am Rev Respir Dis. 1990 Nov;142(5):1015–1021. doi: 10.1164/ajrccm/142.5.1015. [DOI] [PubMed] [Google Scholar]
  97. Smith J. P., Jr, Falk G. A., Siskind G. W. Serum immunoglobulins and alpha-1-antitrypsin: variation with clinical type of chronic obstructive pulmonary disease. Chest. 1971 May;59(Suppl):17S+–17S+. doi: 10.1378/chest.59.5_supplement.17s. [DOI] [PubMed] [Google Scholar]
  98. Sveger T. Plasma protease inhibitors in alpha 1-antitrypsin-deficient children. Pediatr Res. 1985 Aug;19(8):834–835. doi: 10.1203/00006450-198508000-00011. [DOI] [PubMed] [Google Scholar]
  99. Szczeklik A., Stankowska K., Frydecka I. Cardiopulmonary function in 1 -antitrypsin heterozygotes exposed to severe air pollution. Am Rev Respir Dis. 1973 Feb;107(2):289–291. doi: 10.1164/arrd.1973.107.2.289. [DOI] [PubMed] [Google Scholar]
  100. Talamo R. C., Allen J. D., Kahan M. G., Auste K. F. Hereditary alpha-1-antitrypsin deficiency. N Engl J Med. 1968 Feb 15;278(7):345–351. doi: 10.1056/NEJM196802152780701. [DOI] [PubMed] [Google Scholar]
  101. Talamo R. C., Langley C. E., Levine B. W., Kazemi H. Genetic vs. quantitative analysis of serum alpha 1 -antitrypsin. N Engl J Med. 1972 Nov 23;287(21):1067–1069. doi: 10.1056/NEJM197211232872104. [DOI] [PubMed] [Google Scholar]
  102. Tarján E., Magyar P., Váczi Z., Lantos A., Vaszár L. Longitudinal lung function study in heterozygous PiMZ phenotype subjects. Eur Respir J. 1994 Dec;7(12):2199–2204. doi: 10.1183/09031936.94.07122199. [DOI] [PubMed] [Google Scholar]
  103. Tattersall S. F., Pereira R. P., Hunter D., Blundell G., Pride N. B. Lung distensibility and airway function in intermediate alpha 1-antitrypsin deficiency (Pi MZ). Thorax. 1979 Oct;34(5):637–646. doi: 10.1136/thx.34.5.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Turino G. M., Barker A. F., Brantly M. L., Cohen A. B., Connelly R. P., Crystal R. G., Eden E., Schluchter M. D., Stoller J. K. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1718–1725. doi: 10.1164/ajrccm.154.6.8970361. [DOI] [PubMed] [Google Scholar]
  105. Vance J. C., Hall W. J., Schwartz R. H., Hyde R. W., Roghmann K. J., Mudholkar G. C. Heterozygous alpha-1-antitrypsin deficiency and respiratory function in children. Pediatrics. 1977 Sep;60(3):263–272. [PubMed] [Google Scholar]
  106. Varpela E., Salorinne Y. Respiratory disease profile in 22 patients with alpha 1-antitrypsin deficiencies. Scand J Respir Dis Suppl. 1974;89:251–260. [PubMed] [Google Scholar]
  107. Webb D. R., Hyde R. W., Schwartz R. H., Hall W. J., Condemi J. J., Townes P. L. Serum alpha 1-antitrypsin variants. Prevalence and clinical spirometry. Am Rev Respir Dis. 1973 Oct;108(4):918–925. doi: 10.1164/arrd.1973.108.4.918. [DOI] [PubMed] [Google Scholar]
  108. Welch M. H., Reinecke M. E., Hammarsten J. F., Guenter C. A. Antitrypsin deficiency in pulmonary disease: the significance of intermediate levels. Ann Intern Med. 1969 Sep;71(3):533–542. doi: 10.7326/0003-4819-71-3-533. [DOI] [PubMed] [Google Scholar]
  109. Wencker M., Marx A., Konietzko N., Schaefer B., Campbell E. J. Screening for alpha1-Pi deficiency in patients with lung diseases. Eur Respir J. 2002 Aug;20(2):319–324. doi: 10.1183/09031936.02.02012001. [DOI] [PubMed] [Google Scholar]
  110. Zhu Y. J. Epidemiological survey of chronic obstructive pulmonary disease and alpha-1-deficiency in China. Respirology. 2001 Jun;6 (Suppl):S13–S15. doi: 10.1046/j.1440-1843.2001.00306.x. [DOI] [PubMed] [Google Scholar]
  111. de Hamel F. A., Carrell R. W. Heterozygous alpha 1-antitrypsin deficiency: a longitudinal lung function study. N Z Med J. 1981 Dec 9;94(697):407–410. [PubMed] [Google Scholar]
  112. de Serres Frederick J. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest. 2002 Nov;122(5):1818–1829. doi: 10.1378/chest.122.5.1818. [DOI] [PubMed] [Google Scholar]
  113. von Ehrenstein O. S., von Mutius E., Maier E., Hirsch T., Carr D., Schaal W., Roscher A. A., Olgemöller B., Nicolai T., Weiland S. K. Lung function of school children with low levels of alpha1-antitrypsin and tobacco smoke exposure. Eur Respir J. 2002 Jun;19(6):1099–1106. doi: 10.1183/09031936.02.00104302. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES